HBM Holdings Limited

HKSE 2142.HK

HBM Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2023: 16.16%

HBM Holdings Limited Return on Capital Employed (ROCE) is 16.16% for the year ending December 31, 2023, a 120.54% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

HBM Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -78.65%, a -37.87% change year over year.
HBM Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -57.04%, a 30.13% change year over year.
HBM Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -81.65%, a 37.55% change year over year.
HBM Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -130.75%, a -180.12% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

HKSE: 2142.HK

HBM Holdings Limited

CEO	Dr. Jingsong Wang M.D., Ph.D.
IPO Date	Dec. 10, 2020
Location	China
Headquarters	Tower A, 12th Floor
Employees	182
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Key trends

Past 5 years